UNSPSC 51262501: Betanidine or bethanidine

This classification denotes an adrenergic antagonist with the molecular formula C10H15N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W8S3YM7AUU, chemically known as 2-benzyl-1,3-dimethylguanidine but generally known as betanidine, which bears US NIH Compound Identifier 2368. Betanidine most often comes in base and sulfate forms. European Medicines Agency schedules Betanidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05801MIG. The term BETANIDINE is an International Non-Proprietary Name.

UNSPSC 51262501 Betanidine or bethanidine is a Commodity code that shows a significant mismatch between its nominal scope and recent state and local procurement activity. The code's abstract pharmaceutical descriptor does not align with the two recent opportunities posted under it: Seminole County, Florida's IFB for naloxone and drug deactivation systems, and the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs. Neither solicitation involves betanidine or bethanidine procurement, and the opportunities reflect broader pharmaceutical supply, emergency response products, and pharmacy benefit management instead. This disconnect suggests either miscoding by the issuing bodies or that the UNSPSC taxonomy entry does not accurately capture state and local buying patterns in this pharmaceutical space.

The recent opportunities span a county health department and a state HHS agency, indicating fragmented issuing-body participation without a clear pattern of repeat buyers under this code. Seminole County's naloxone procurement (IFB 60459723LAS, due July 26, 2023) sought 1,900 units annually with quarterly deliveries, requiring electronic bidding through the county's e-Procurement Portal and compliance with drug-free workplace and E-Verify standards. The Texas HHS Commission's RFI (HHS0017013, posted April 3, 2026) was exploratory in nature, gathering vendor capabilities for direct-to-manufacturer prescription contracting outside traditional pharmacy benefit manager and group purchasing organization channels. Activity appears concentrated in Florida and Texas with no evidence of broader geographic distribution. The code shows minimal recent procurement activity aligned with its stated scope, and business development professionals should verify coding accuracy with issuing bodies before pursuing opportunities tagged under this Commodity code.